FIORETTI, Maria Cristina
 Distribuzione geografica
Continente #
NA - Nord America 3.736
EU - Europa 2.690
AS - Asia 2.568
SA - Sud America 502
Continente sconosciuto - Info sul continente non disponibili 187
AF - Africa 80
OC - Oceania 4
Totale 9.767
Nazione #
US - Stati Uniti d'America 3.649
SG - Singapore 1.298
UA - Ucraina 587
IE - Irlanda 440
BR - Brasile 381
CN - Cina 334
SE - Svezia 326
RU - Federazione Russa 313
HK - Hong Kong 295
IT - Italia 275
VN - Vietnam 263
DE - Germania 229
FI - Finlandia 149
FR - Francia 147
KR - Corea 73
IN - India 72
GB - Regno Unito 71
BD - Bangladesh 60
AR - Argentina 40
CA - Canada 31
TR - Turchia 28
MX - Messico 26
PL - Polonia 25
ZA - Sudafrica 25
CO - Colombia 24
CZ - Repubblica Ceca 22
IQ - Iraq 20
EC - Ecuador 19
CH - Svizzera 16
NL - Olanda 16
BE - Belgio 14
ES - Italia 14
JP - Giappone 14
PK - Pakistan 14
AT - Austria 13
UZ - Uzbekistan 13
GR - Grecia 12
CI - Costa d'Avorio 10
PH - Filippine 10
SA - Arabia Saudita 10
LB - Libano 9
VE - Venezuela 9
CL - Cile 8
ID - Indonesia 8
KE - Kenya 8
PE - Perù 8
AZ - Azerbaigian 7
JO - Giordania 7
TN - Tunisia 7
EG - Egitto 6
JM - Giamaica 6
BO - Bolivia 5
CR - Costa Rica 5
IL - Israele 5
LT - Lituania 5
MA - Marocco 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
ET - Etiopia 4
MY - Malesia 4
PS - Palestinian Territory 4
EU - Europa 3
KZ - Kazakistan 3
LC - Santa Lucia 3
PA - Panama 3
RS - Serbia 3
UY - Uruguay 3
AU - Australia 2
GT - Guatemala 2
LK - Sri Lanka 2
LR - Liberia 2
LV - Lettonia 2
MN - Mongolia 2
NG - Nigeria 2
OM - Oman 2
PT - Portogallo 2
RO - Romania 2
SC - Seychelles 2
SV - El Salvador 2
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CU - Cuba 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
ML - Mali 1
Totale 9.570
Città #
Singapore 919
Chandler 494
Dublin 440
Hong Kong 291
San Mateo 271
Jacksonville 252
San Jose 230
Boardman 165
Ashburn 155
Santa Clara 143
Dong Ket 116
Altamura 114
Medford 108
Princeton 108
Des Moines 103
Moscow 95
Wilmington 93
Lauterbourg 92
Lawrence 86
Beijing 85
Ann Arbor 72
Perugia 69
Seoul 69
Munich 67
Andover 62
Ho Chi Minh City 50
New York 48
Falls Church 47
São Paulo 42
Los Angeles 38
The Dalles 38
Saint Petersburg 36
Hanoi 34
Turku 28
Norwalk 27
Dearborn 26
Piscataway 26
Woodbridge 23
Dallas 21
Orem 20
Chennai 19
Frankfurt am Main 19
San Paolo di Civitate 19
Brooklyn 17
Warsaw 15
Brussels 14
Johannesburg 14
Milan 14
Brno 13
Chicago 13
Helsinki 13
Shanghai 13
Nuremberg 12
Tokyo 12
Abidjan 10
Boston 10
Haiphong 10
Houston 10
Montreal 10
Atlanta 9
Baghdad 9
Columbus 9
Fremont 9
Mexico City 9
Mumbai 9
Denver 8
London 8
Medellín 8
Nairobi 8
Phoenix 8
Rio de Janeiro 8
Cambridge 7
Fortaleza 7
Guayaquil 7
Izmir 7
Manchester 7
Toronto 7
Amman 6
Ankara 6
Belo Horizonte 6
Den Haag 6
Jinan 6
Nagpur 6
Olomouc 6
Poplar 6
Amsterdam 5
Auburn Hills 5
Baku 5
Brasília 5
Buffalo 5
Cape Town 5
Charlotte 5
Falkenstein 5
Goiânia 5
Hefei 5
Jeddah 5
Lausanne 5
Nanjing 5
Philadelphia 5
Riyadh 5
Totale 5.727
Nome #
Accelerated hematopoietic recovery and protective effect of the cyclooxygenase inhibitor indomethacin in bacterial infection of neutropenic mice. 162
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy 149
A retroviral peptide encoded by mutated env p15E gene is recognized by specific CD8+ T lymphocytes on drug-treated murine mastocytoma P815. 149
CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide 147
Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. 143
3H-aniracetam binds to specific recognition sites in brain membranes 141
T cell apoptosis by kynurenines. 138
CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. 131
Immunogenic tumor variants induced by drug treatment of the L5178Y lymphoma: search for serologically defined antigens at the clonal level. 131
Cell-mediated immunity to chemically xenogenized tumors--IV. Production of lymphokine activity by, and in response to, highly immunogenic cells. 130
Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells. 124
Dual effect of IL-4 on resistance to systemic gram-negative infection and production on TNF-alfa 122
T-cell subsets, IFN-gamma production and efferent specificity in anti-parental tumor immunity induced by mouse sensitization with xenogenized variant cells. 120
Evidence for tumor necrosis factor alpha as a mediator of the toxicity of a cyclooxygenase inhibitor in Gram-negative sepsis. 120
CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig. 120
Antilymphoma graft responses in the mouse brain: a study of T-dependent functions. 119
CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice 117
Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations. 117
IL-12 acts selectively on CD8a- dendritic cells to enhance presentation of a tumor peptide in vivo 115
Appearance of strong transplantation antigens in non-immunogenic lymphoma following drug-treatment in vivo. 115
Antigenic changes related to drug action. 115
Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation 114
Antitumor activity of three nitrosourea analogues in different experimental tumor system 113
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells 112
A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state 110
CD40 ligand and CTLA-4 are reciprocally regulated in the Th1 cell proliferative response sustained by CD8+ dendritic cells. 109
Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens. 109
Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. 105
Modulation of tryptophan catabolism by regulatory T cells 104
Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease 102
Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. 101
[In vitro cytolysis mediated by NK effectors: modification of the susceptibility of the target cell by in vivo treatment with DTIC]. 101
CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells 100
Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine 98
IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. 98
Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. 98
A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice 98
Towards the identification of a tolerogenic signature in IDO-competent dendritic cells 97
Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12 97
CTLA-4-Ig regulates tryptophan catabolism in vivo. 96
T cell apoptosis by tryptophan catabolism 96
Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. 96
Cell-mediated immunity to chemically xenogenized tumors--III. Generation of monoclonal antibodies interfering with reactivity to novel antigens. 96
Indoleamine 2,3-dioxygenase, transcriptional regulation and autoimmunity. 95
Antigenic properties of lymphoma sublines derived from a drug-treated immunogenic L5178Y leukemia. 95
Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma 94
Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. 93
Cell-mediated immunity to chemically xenogenized tumors. II. Evidence for accessory function and self-antigen presentation by a highly immunogenic tumor variant. 93
IL-9 protects mice from Fram-negative bacterial shock: suppression of alfa-TNF, IL-12 and gamma-IFN, and induction of IL-10. 92
IL-12 ACTS DIRECTLY ON DC TO PROMOTE NUCLEAR LOCALIZATION OF NF-kB AND PRIMES DC FOR IL-12 PRODUCTION 90
Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. 89
IL-23 neutralization protects mice from Gram-negative endotoxic shock. 89
Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. 89
Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity 88
Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement 88
Tryptophan catabolism generates autoimmune-preventive regulatory T cells 87
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells 87
IL-12 induces SDS-stable class II (alpha beta) dimers in murine dendritic cells 86
IL-23 and IL-12 have overlapping but distinct effects on murine dendritic cells. 85
Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization. 85
In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo. 85
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis 84
Cell-mediated immunity to chemically xenogenized tumors. V. Failure of novel antigens to increase the frequency of tumor-specific cytotoxic T cells. 83
Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity. 81
Systemic adoptive immunotherapy of a highly immunogenic murine lymphoma growing in the brain. 81
Immunogenic properties of retroviral protein p15E from drug-treated murine mastocytoma P815 80
Endogenous retroviral gp70 genes of the murine lymphoma L5178Y: analysis of restriction fragment polymorphism upon induction of drug-mediated immunogenicity. 80
Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. 79
Identification and immunogenic properties of an 80-kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. 79
Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex 78
Inhibition of murine lymphoma growth by adoptive transfer of lymphocytes sensitized to a xenogenized tumor variant. 78
IDO mediates TLR9-driven protection from experimental autoimmune diabetes 77
Cell-mediated immunity to chemically xenogenized tumors--VI. The effect of cell treatment with retroviral env antisense oligonucleotides. 77
Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation 76
DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives. 76
IL-12 is both required and sufficient for initiating T-cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells 75
Cell-mediated immunity to chemically xenogenized tumors. II. Evidence for accessory function and self-antigen presentation by a highly immunogenic tumor variant. 74
T-cell subsets, IFN-gamma production and efferent specificity in anti-parental tumor immunity induced by mouse sensitization with xenogenized variant cells. 74
Tumor-specific L3T4+ and Lyt-2+ lymphocytes in mice primed to mutagenized cell variants. 73
Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative. 73
Rational bases of cancer immunochemotherapy: drug effects on antigen expression 73
Chemical xenogenization of tumor cells. 72
Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies. 72
Intracerebral adoptive immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo. 71
Cytokines and tumours: problems and perspectives. 70
Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives. 70
Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. 70
Susceptibility of murine lymphoma cells treated with 5-(3,3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide to NK-mediated cytotoxicity in vitro. 69
Identification and immunogenic properties of an 80-kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. 69
Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines. 67
Immune system to brain signaling and vice versa: The role of tryptophan and glutamate 66
Expression of normal histocompatibility antigens in murine lymphomas treated with 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vivo. 64
Lack of correlation between DNA-methylating activity and appearance of the immunogenic phenotype in clones of a murine lymphoma treated with mutagens. 63
Induction of tumor suppression and delayed-type footpad reaction by transfer of lymphocytes sensitized to a xenogenized tumor variant. 62
Molecular and genomic aspects of xenogenizing-alkylating drugs. 61
Regulation of tumor antigen expression by drugs acting as mutagens and/or gene activators. 60
O6-methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents. 60
Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone 60
I Chemioterapici 59
Tryptophan catabolism in nonobese diabetic mice. 59
Totale 9.380
Categoria #
all - tutte 43.487
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.487


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022946 0 168 9 56 73 27 16 302 18 29 74 174
2022/20231.664 128 295 15 124 145 247 1 87 556 5 47 14
2023/2024509 44 88 19 6 3 2 108 7 65 8 71 88
2024/20251.357 21 125 77 42 195 61 11 81 265 91 252 136
2025/20263.111 197 258 166 403 354 272 557 213 320 264 74 33
2026/2027144 74 70 0 0 0 0 0 0 0 0 0 0
Totale 9.767